NASDAQ:PCRX - Pacira Pharmaceuticals Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $36.40 -0.10 (-0.27 %) (As of 07/16/2018 06:17 AM ET)Previous Close$36.50Today's Range$36.15 - $37.1052-Week Range$26.95 - $51.10Volume374,806 shsAverage Volume716,292 shsMarket Capitalization$1.48 billionP/E Ratio-62.76Dividend YieldN/ABeta1.79 Company ProfileFinancialsAnalyst RatingsEarnings HistoryInsider TradesHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Pacira Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and commercializes proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the United States. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology. The company's lead product includes, EXPAREL, a liposome injection of bupivacaine, an amide-type local anesthetic indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. The company was formerly known as Pacira, Inc. and changed its name to Pacira Pharmaceuticals, Inc. in October 2010. Pacira Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Parsippany, New Jersey. Receive PCRX News and Ratings via Email Sign-up to receive the latest news and ratings for PCRX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals SectorMedical SymbolNASDAQ:PCRX CUSIP69512710 Webwww.pacira.com Phone973-254-3560 Debt Debt-to-Equity Ratio1.00 Current Ratio8.66 Quick Ratio7.83 Price-To-Earnings Trailing P/E Ratio-62.76 Forward P/E Ratio-63.86 P/E GrowthN/A Sales & Book Value Annual Sales$286.63 million Price / Sales5.17 Cash Flow$0.0614 per share Price / Cash592.59 Book Value$6.89 per share Price / Book5.28 Profitability EPS (Most Recent Fiscal Year)($0.58) Net Income$-42,610,000.00 Net Margins-11.45% Return on Equity-5.81% Return on Assets-2.56% Miscellaneous Employees489 Outstanding Shares40,730,000Market Cap$1,482.64 Pacira Pharmaceuticals (NASDAQ:PCRX) Frequently Asked Questions What is Pacira Pharmaceuticals' stock symbol? Pacira Pharmaceuticals trades on the NASDAQ under the ticker symbol "PCRX." How were Pacira Pharmaceuticals' earnings last quarter? Pacira Pharmaceuticals Inc (NASDAQ:PCRX) announced its quarterly earnings results on Thursday, May, 3rd. The company reported $0.02 earnings per share (EPS) for the quarter, hitting the Thomson Reuters' consensus estimate of $0.02. The business earned $74.61 million during the quarter, compared to the consensus estimate of $73.92 million. Pacira Pharmaceuticals had a negative return on equity of 5.81% and a negative net margin of 11.45%. Pacira Pharmaceuticals's revenue was up 7.7% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.19) earnings per share. View Pacira Pharmaceuticals' Earnings History. When is Pacira Pharmaceuticals' next earnings date? Pacira Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, July, 31st 2018. View Earnings Estimates for Pacira Pharmaceuticals. What price target have analysts set for PCRX? 21 brokers have issued 12-month price objectives for Pacira Pharmaceuticals' shares. Their forecasts range from $27.00 to $80.00. On average, they expect Pacira Pharmaceuticals' stock price to reach $45.1765 in the next year. This suggests a possible upside of 24.1% from the stock's current price. View Analyst Ratings for Pacira Pharmaceuticals. What is the consensus analysts' recommendation for Pacira Pharmaceuticals? 21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pacira Pharmaceuticals in the last year. There are currently 1 sell rating, 11 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Hold." What are Wall Street analysts saying about Pacira Pharmaceuticals stock? Here are some recent quotes from research analysts about Pacira Pharmaceuticals stock: 1. According to Zacks Investment Research, "Pacira’s top line mainly comprises contribution from its marketed product-Exparel. It is making efforts to expand Exparel's label. In April 2018, the FDA approved Pacira’s sNDA seeking expansion of the Exparel label to include administration via nerve block for prolonged regional analgesia. However, the company is heavily dependent on Exparel for growth, which accounts for a significant chunk of its revenues. This is a concern for the company. Exparel also competes with well-established products for postsurgical pain management." (7/15/2018) 2. HC Wainwright analysts commented, "Valuation and risks. Our $48 12-month target is based on an average of our $55/share DCF (10% WACC discount rate; 1% terminal growth beyond 2024) and a $41/share P/E multiple derived valuation (30x fully-taxed 2020 EPS, or 1x PEG, discounted back)." (7/10/2018) 3. Mizuho analysts commented, "We switched from Symphony Health data last month, after a sizeable data restatement from the vendor rendered our prior estimates unreliable." (6/29/2018) 4. Canaccord Genuity analysts commented, "We’re looking for more than two months of data showing solid growth before we become positive on the potential for a meaningful inflection in Exparel use trends, especially with a noisy October that may have benefited from hurricane-related deferred procedures that negatively impacted September volumes. We remain HOLD rated on PCRX shares." (12/29/2017) Who are some of Pacira Pharmaceuticals' key competitors? Some companies that are related to Pacira Pharmaceuticals include Catalent (CTLT), Ionis Pharmaceuticals (IONS), Dr.Reddy's Laboratories (RDY), United Therapeutics (UTHR), Loxo Oncology (LOXO), FibroGen (FGEN), Agios Pharmaceuticals (AGIO), GALAPAGOS NV/S (GLPG), Ligand Pharmaceuticals (LGND), Taro Pharmaceutical Industries (TARO), Madrigal Pharmaceuticals (MDGL), GW Pharmaceuticals (GWPH), HUTCHISON CHINA/S (HCM), Ultragenyx Pharmaceutical (RARE) and Array Biopharma (ARRY). Who are Pacira Pharmaceuticals' key executives? Pacira Pharmaceuticals' management team includes the folowing people: Mr. David M. Stack, Chairman and Chief Exec. Officer (Age 68)Mr. Charles A. Reinhart III, Chief Financial Officer (Age 57)Ms. Kristen Williams J.D., Chief Admin. Officer, Gen. Counsel and Sec. (Age 44)Ms. Lauren Bullaro Riker, Principal Accounting Officer & VP of Fin. (Age 39)Dr. Richard Scranton M.D., MPH, Chief Scientific Officer Has Pacira Pharmaceuticals been receiving favorable news coverage? News articles about PCRX stock have trended somewhat positive recently, Accern Sentiment Analysis reports. The research firm identifies positive and negative media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Pacira Pharmaceuticals earned a daily sentiment score of 0.12 on Accern's scale. They also gave media headlines about the company an impact score of 46.06 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future. Who are Pacira Pharmaceuticals' major shareholders? Pacira Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Peregrine Capital Management LLC (0.66%) and Xact Kapitalforvaltning AB (0.02%). Company insiders that own Pacira Pharmaceuticals stock include Charles A Reinhart III, David M Stack, James B Jones, James S Scibetta, Kristen Marie Williams, Lauren Bullaro Riker, Mark A Kronenfeld, Mark Froimson, Paul J Hastings, Richard Scranton and Scott Braunstein. View Institutional Ownership Trends for Pacira Pharmaceuticals. Which major investors are selling Pacira Pharmaceuticals stock? PCRX stock was sold by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC. Company insiders that have sold Pacira Pharmaceuticals company stock in the last year include Charles A Reinhart III, David M Stack, James B Jones, Kristen Marie Williams, Lauren Bullaro Riker, Paul J Hastings and Richard Scranton. View Insider Buying and Selling for Pacira Pharmaceuticals. Which major investors are buying Pacira Pharmaceuticals stock? PCRX stock was purchased by a variety of institutional investors in the last quarter, including Xact Kapitalforvaltning AB. Company insiders that have bought Pacira Pharmaceuticals stock in the last two years include Mark A Kronenfeld and Mark Froimson. View Insider Buying and Selling for Pacira Pharmaceuticals. How do I buy shares of Pacira Pharmaceuticals? Shares of PCRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Pacira Pharmaceuticals' stock price today? One share of PCRX stock can currently be purchased for approximately $36.40. How big of a company is Pacira Pharmaceuticals? Pacira Pharmaceuticals has a market capitalization of $1.48 billion and generates $286.63 million in revenue each year. The company earns $-42,610,000.00 in net income (profit) each year or ($0.58) on an earnings per share basis. Pacira Pharmaceuticals employs 489 workers across the globe. How can I contact Pacira Pharmaceuticals? Pacira Pharmaceuticals' mailing address is 5 SYLVAN WAY SUITE 300, PARSIPPANY NJ, 07054. The company can be reached via phone at 973-254-3560 or via email at [email protected] MarketBeat Community Rating for Pacira Pharmaceuticals (NASDAQ PCRX)Community Ranking: 3.1 out of 5 ( )Outperform Votes: 585 (Vote Outperform)Underperform Votes: 366 (Vote Underperform)Total Votes: 951MarketBeat's community ratings are surveys of what our community members think about Pacira Pharmaceuticals and other stocks. Vote "Outperform" if you believe PCRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PCRX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/16/2018 by MarketBeat.com StaffFeatured Article: What are Closed-End Mutual Funds?